Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-primidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy

被引:68
作者
Kamiryo, T [1 ]
Tada, K [1 ]
Shiraishi, S [1 ]
Shinojima, N [1 ]
Kochi, M [1 ]
Ushio, Y [1 ]
机构
[1] Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 860, Japan
关键词
high-grade astrocytic tumors; O-6-methylguanine-deoxyribonucleic acid methyltransferase gene; prognosis; promoter hypermethylation;
D O I
10.1227/01.NEU.0000103422.51382.99
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECTIVE: O-6-Methylguanine deoxyribonucleic acid methyltransferase (MGMT) is a deoxyribonucleic acid repair protein associated with the chemoresistance of chloroethyl nitrosoureas. we investigated whether MGMT promoter hypermethylation is associated with prognosis in patients with high-grade astrocytic tumors treated uniformly with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU)-based chemotherapy. METHODS: Using the methylation-specific polymerase chain reaction, we assayed promoter hypermethylation of the MGMT gene in tumor deoxyribonucleic acid from 116 adult patients with supratentorial high-grade astrocytic tumors (42 anaplastic astrocytomas [AAs] and 74 glioblastomas multiforme [GBMs]). The Cox proportional hazards model was used in forward stepwise regression to assess the relative role of prognostic factors (i.e., age at surgery, sex, Karnofsky Performance Scale score, extent of surgical resection, methylation status of the MGMT promoter, and association MGMT promoter methylation and survival). between RESULTS: MGMT promoter hypermethylation was confirmed in 19 (45.2%) of 42 AA patients and 33 (44.6%) of 74 GBM patients. It was significantly associated with both longer overall and progression-free survival time in AA but not GBM patients. CONCLUSION: Our results demonstrate that MGMT promoter hypermethylation is associated with longer survival time in patients with AA who were treated with surgery, radiotherapy, and ACNU-based chemotherapy but not in patients with GBM.
引用
收藏
页码:349 / 357
页数:9
相关论文
共 32 条
[1]  
AIDA T, 1987, CANCER RES, V47, P5052
[2]  
[Anonymous], 2000, World Health Organisation Classification of Tumours: Pathology and genetics of tumours of the nervous system
[3]  
Belanich M, 1996, CANCER RES, V56, P783
[4]   CONTRIBUTION OF O-6-METHYLGUANINE-DNA METHYLTRANSFERASE TO RESISTANCE TO 1,3-(2-CHLOROETHYL)-1-NITROSOUREA IN HUMAN BRAIN TUMOR-DERIVED CELL-LINES [J].
BOBOLA, MS ;
BERGER, MS ;
SILBER, JR .
MOLECULAR CARCINOGENESIS, 1995, 13 (02) :81-88
[5]  
CHANG CH, 1983, CANCER, V52, P997, DOI 10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO
[6]  
2-2
[7]  
Costello JF, 1996, CANCER RES, V56, P2405
[8]   DEFECTIVE REPAIR OF ALKYLATED DNA BY HUMAN-TUMOR AND SV40-TRANSFORMED HUMAN CELL STRAINS [J].
DAY, RS ;
ZIOLKOWSKI, CHJ ;
SCUDIERO, DA ;
MEYER, SA ;
LUBINIECKI, AS ;
GIRARDI, AJ ;
GALLOWAY, SM ;
BYNUM, GD .
NATURE, 1980, 288 (5792) :724-727
[9]   Sex differences in length of survival with malignant astrocytoma, but not with glioblastoma [J].
Diete, S ;
Treuheit, T ;
Dietzmann, K ;
Schmidt, U ;
Wallesch, CW .
JOURNAL OF NEURO-ONCOLOGY, 2001, 53 (01) :47-49
[10]   DNA CROSS-LINKING AND MONOADDUCT REPAIR IN NITROSOUREA-TREATED HUMAN-TUMOR CELLS [J].
ERICKSON, LC ;
LAURENT, G ;
SHARKEY, NA ;
KOHN, KW .
NATURE, 1980, 288 (5792) :727-729